Background: BMS-747158-02 is a novel fluorine 18-labeled pyridazinone derivative designed for cardiac imaging. The uptake and retention mechanisms of F-18 BMS-747158-02 in cardiac myocytes were studied in vitro, and the biodistribution of F-18 BMS-747158-02 was studied in vivo in mice.
Methods And Results: Fluorine 19 BMS-747158-01 inhibited mitochondrial complex I (MC-I) in bovine heart submitochondrial particles with an IC(50) of 16.6 +/- 3 nmol/L that was comparable to the reference inhibitors of MC-1, rotenone, pyridaben, and deguelin (IC(50) of 18.2 +/- 6.7 nmol/L, 19.8 +/- 2.6 nmol/L, and 23.1 +/- 1.5 nmol/L, respectively). F-18 BMS-747158-02 had high uptake in monolayers of neonatal rat cardiomyocytes (10.3% +/- 0.7% of incubated drug at 60 minutes) that was inhibited by 200 nmol/L of rotenone (91% +/- 2%) and deguelin (89% +/- 3%). In contrast, an inactive pyridaben analog, P-070 (IC(50) value >4 micromol/L in MC-1 assay), did not inhibit the binding of F-18 BMS-747158-02 in cardiomyocytes. Uptake and washout kinetics for F-18 BMS-747158-02 in rat cardiomyocytes indicated that the time to half-maximal (t((1/2))) uptake was very rapid (approximately 35 seconds), and washout t((1/2)) for efflux of F-18 BMS-747158-02 was greater than 120 minutes. In vivo biodistribution studies in mice showed that F-18 BMS-747158-02 had substantial myocardial uptake (9.5% +/- 0.5% of injected dose per gram) at 60 minutes and heart-to-lung and heart-to-liver ratios of 14.1 +/- 2.5 and 8.3 +/- 0.5, respectively. Positron emission tomography imaging in the mouse allowed clear cardiac visualization and demonstrated sustained myocardial uptake through 55 minutes.
Conclusions: F-18 BMS-747158-02 is a novel positron emission tomography cardiac tracer targeting MC-I in cardiomyocytes with rapid uptake and slow washout. These characteristics allow fast and sustained accumulation in the heart.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nuclcard.2007.07.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase I clinical study of NMB58, a novel positron emission tomography (PET)-myocardial perfusion imaging tracer, conducted to evaluate its safety and pharmacokinetics in Japanese healthy adult males.
Ann Nucl Med
May 2021
Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, -5-45 Yushima, Bunkyo-ku, Tokyo, 113 - 8510, Japan.
Article Synopsis
- NMB58 is a new PET tracer that targets mitochondrial complex 1 and was tested for safety and pharmacokinetics in a Phase I study with healthy participants.
- Ten Japanese volunteers received NMB58 injections and underwent imaging, with assessments of safety and radiation exposure over several days, including stress tests on day 2.
- Results showed that the myocardium and kidneys had the highest radiation doses, but NMB58's exposure levels were similar to or lower than existing approved tracers, with good retention in heart tissue.
Assessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) injection for positron emission tomography (PET) imaging.
J Nucl Cardiol
June 2021
Division of Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Article Synopsis
- The study focuses on the safety and effectiveness of Fluorine-18 Flurpiridaz in diagnosing coronary artery disease (CAD) through PET myocardial perfusion imaging (MPI), as indicated by successful previous clinical trials.
- The primary goal is to evaluate how well F-18 Flurpiridaz PET MPI detects clinically significant CAD compared to invasive coronary angiography, with secondary comparisons against another imaging technique (SPECT).
- This trial modifies the design of a prior phase 3 study by excluding patients with known CAD, changing study endpoints, and ensuring both imaging methods are performed before confirming CAD through angiography.
Diagnostic Performance of PET Versus SPECT Myocardial Perfusion Imaging in Patients with Smaller Left Ventricles: A Substudy of the F-Flurpiridaz Phase III Clinical Trial.
J Nucl Med
June 2021
Division of Cardiology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California.
Article Synopsis
- SPECT myocardial perfusion imaging (MPI) struggles with smaller hearts due to lower resolution, while the new PET MPI agent, F-flurpiridaz, offers better image quality and accuracy.
- A study compared the diagnostic performance of traditional SPECT with F-flurpiridaz PET based on left ventricle (LV) size, revealing significant degradation in SPECT's sensitivity for smaller LVs, while PET maintained consistent performance.
- Overall, F-flurpiridaz PET MPI demonstrated significantly higher sensitivity than SPECT for both small and large LVs, indicating it is a more reliable imaging technique regardless of heart size.
Preliminary and Comparative Experiment Study Between F-Flurpiridaz and N-NHHO Myocardial Perfusion Imaging With PET/CT in Miniature Pigs.
Mol Imaging
July 2021
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Article Synopsis
- The study investigates the effectiveness of F-Flurpiridaz versus N-NH·HO in PET/CT myocardial perfusion imaging using mini pigs with different heart health conditions.
- F-Flurpiridaz showed rapid distribution in the heart and minimal background interference, leading to high-quality images without significant differences in key cardiac function metrics when compared to N-NH·HO.
- The findings suggest that F-Flurpiridaz is a promising imaging agent for evaluating heart function due to its superior image quality and ease of use.
[ F]Flurpiridaz: Facile and Improved Precursor Synthesis for this Next-Generation Cardiac Positron Emission Tomography Imaging Agent.
ChemMedChem
June 2020
Institute of Pharmaceutical Sciences Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 4, 8093, Zürich, Switzerland.
Article Synopsis
- Flurpiridaz is a new PET tracer in phase III trials aimed at measuring blood flow in the heart, potentially setting a new standard for early detection of coronary artery disease due to its favorable properties.
- The original production process of Flurpiridaz involved a dangerous step with carcinogenic chemicals and had a low yield of only 7%, but researchers increased the yield over fivefold and eliminated the hazardous step.
- The binding specificity of Flurpiridaz to mitochondrial complex 1 was confirmed through experiments on mouse heart tissue, which supports its use in studying heart blood flow and related cardiovascular issues in animal models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!